Cargando…

The Different Roles of MET in the Development and Treatment of Cancer

Detalles Bibliográficos
Autores principales:	Mollerup, Jens, Jørgensen, Jan Trøst
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605179/ https://www.ncbi.nlm.nih.gov/pubmed/37894454 http://dx.doi.org/10.3390/cancers15205087

Ejemplares similares

Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
por: Jørgensen, Jan Trøst, et al.
Publicado: (2022)

MET deletion is a frequent event in gastric/gastroesophageal junction/esophageal cancer: a cross-sectional analysis of gene status and signal distribution in 1,580 patients
por: Jørgensen, Jan Trøst, et al.
Publicado: (2021)

A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer
por: Jørgensen, Jan Trøst, et al.
Publicado: (2021)

Gene Signal Distribution and HER2 Amplification in Gastroesophageal Cancer
por: Jørgensen, Jan Trøst, et al.
Publicado: (2017)

Interactions between CKD and MetS and the Development of CVD
por: Aihara, Ken-ichi, et al.
Publicado: (2011)

MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?
por: Pruis, Melinda A., et al.
Publicado: (2020)

HGF-MET as a breast cancer biomarker
por: Liu, Shuying
Publicado: (2015)

MET Inhibitor is Expected to Overcome MET Amplification-Induced Immunotherapy Resistance in Non-Small Cell Lung Cancer
por: Ruan, Ji
Publicado: (2021)

Drug-Diagnostics Co-Development in Oncology
por: Jørgensen, Jan Trøst
Publicado: (2014)

When Harry Met Sally, or When Machine Learning Met Chronic Obstructive Pulmonary Disease
por: Agusti, Alvar, et al.
Publicado: (2020)

Role of cMET in the Development and Progression of Colorectal Cancer
por: Pérez-Vargas, Juan Carlos Samamé, et al.
Publicado: (2013)

Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012)

We Have Met the Enemy, and It Is Us
por: Johnston, Mark
Publicado: (2013)

Should we SUSPEND MET? Not really
por: Sairam, Krishnamurthy
Publicado: (2016)

The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future
por: Woo, Hyun Young, et al.
Publicado: (2020)

Role of MicroRNAs in Cancer Development and Treatment
por: Mehterov, Nikolay
Publicado: (2023)

Critical Role of MetR/MetB/MetC/MetX in Cysteine and Methionine Metabolism, Fungal Development, and Virulence of Alternaria alternata
por: Gai, Yunpeng, et al.
Publicado: (2021)

Latest updates on MET targeted therapy for EXON 14 mutations in lung cancer
por: Al Jaberi, Mira, et al.
Publicado: (2023)

Efficacy and Safety of DWJ1252 Compared With Gasmotin Treatment: Once Met 3 Times Tablets
por: Kim, Jae Hak
Publicado: (2021)

MET in ovarian cancer: Metastasis and resistance?
por: Tang, Chad, et al.
Publicado: (2014)

B2M, JAK2 and MET in the genetic landscape of immunotolerance in lung cancer
por: Sanchez-Cespedes, Montse
Publicado: (2018)

Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?
por: Kujtan, Lara, et al.
Publicado: (2023)

Indian Journal of Ophthalmology - Promises kept, objectives met
por: Honavar, Santosh G
Publicado: (2020)

The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment
por: Parikh, Rahul A, et al.
Publicado: (2014)

Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects
por: Olsen, Dana, et al.
Publicado: (2014)

Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
por: Błaszkowska, M., et al.
Publicado: (2022)

Special Issue: “Role of MicroRNA in Cancer Development and Treatment”
por: Pulliero, Alessandra, et al.
Publicado: (2022)

Devil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC
por: Strickland, Matthew R., et al.
Publicado: (2020)

HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature
por: Jørgensen, Jan Trøst, et al.
Publicado: (2012)

Role of HGF/c‐Met in the treatment of colorectal cancer with liver metastasis
por: Yao, Jian‐feng, et al.
Publicado: (2019)

Oncogene alterations in non-small cell lung cancer—have we MET a new target?
por: Dempke, Wolfram C. M., et al.
Publicado: (2022)

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer
por: Liao, Haiyan, et al.
Publicado: (2021)

Are the conditions met to make COVID-19 vaccination mandatory for healthcare professionals?
por: Gagneux-Brunon, Amandine, et al.
Publicado: (2021)

Role of Met Axis in Head and Neck Cancer
por: Xu, Yiru, et al.
Publicado: (2013)

The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review
por: Hsu, Robert, et al.
Publicado: (2023)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma
por: Santoni-Rugiu, Eric, et al.
Publicado: (2021)

Editorial of Special Issue “New Aspects of the Hepatocyte Growth Factor/c-Met System”
por: Ricci, Giulia
Publicado: (2015)

The role of MET in chemotherapy resistance
por: Wood, Georgina E., et al.
Publicado: (2021)

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_83mpugufc86jldk03ukkdsie2s